This resource is a FAQ document for prospective host organizations of the Fellows Program. For more information visit www.avac.org/fellows.
Frequently Asked Questions for Host Organizations
AVAC Advocacy Fellows Quick Guide for Applicants
Brief two-pager outlining the AVAC Advocacy Fellows program. More information available at www.avac.org/fellows.
HIV Prevention Research & Development Investments 2021
In its 17th annual report, the Resource Tracking for HIV Prevention Research & Development Working Group documents research and development spending for the calendar year 2021. This report also analyzes funding trends spanning 22 years for the following biomedical HIV prevention options: preventive HIV vaccines, microbicides, pre-exposure prophylaxis (PrEP), treatment as prevention (TasP), voluntary medical male circumcision (VMMC), female condoms and prevention of vertical transmission (PVT). More information at hivresourcetracking.org.
Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?
May 17, 2023
With several large HIV vaccine trials in the last few years finding no efficacy, the field is in transition. There are diverse ideas in vaccine research, but there’s no clear concept that’s ready to test in a late-phase trial or move towards product development currently. Researchers are back to testing new ideas in early phase research.
In this episode of our Px Pulse podcast, Evolving Strategies for an HIV Vaccine: One researcher explains where the field is going and why?, Dr. Katy Stephenson explores the implications of recent trial results, the big questions driving next generation vaccine development, and new strategies underway in early phase research. Katy is a doctor, a researcher, a professor of medicine at Harvard Medical School, affiliated with Beth Israel Deaconess Medical Center, and part of the Center for Virology and Vaccine Research.
Listen
Resources
HIV Vaccine Awareness Day (HVAD) 2023
In 2023, AVAC and CASPR partners cast a spotlight on many issues and opportunities for HIV vaccine science. This one-pager highlights key conversations.
Global Investment in HIV Cure Research & Development in 2021
A decade of progress
Language for HIV Cure
This document shares up-to-date, community-preferred terminology within cure research.
A Comprehensive Approach for Progress
Ending the Epidemic
HIV-Specific Neutralizing Antibodies by Target
A number of broadly neutralizing antibodies that target various regions of HIV’s Env protein are being developed for HIV prevention.
The Case For an HIV Cure and How to Get There
Viewpoint appearing in The Lancet HIV
Appearing in The Lancet HIV: We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.